Research programme: PEGylated cytokines - Synageva

Drug Profile

Research programme: PEGylated cytokines - Synageva

Alternative Names: AES-082; AES-091; SBC-091

Latest Information Update: 07 Feb 2011

Price : $50

At a glance

  • Originator Synageva BioPharma
  • Class Cytokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer; Infections

Highest Development Phases

  • No development reported Cancer; Infections

Most Recent Events

  • 07 Feb 2011 No development reported - Preclinical for Cancer in USA (Parenteral)
  • 07 Feb 2011 No development reported - Preclinical for Infections in USA (Parenteral)
  • 03 Oct 2008 PEGylated cytokine programme is available for licensing and/or co-development in the USA (http://www.synageva.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top